One-Third of Indian Children Age 5–9 Estimated to Have High Triglycerides

IMT News Desk
IMT News Desk
· 2 min read

A newly released government report reveals that more than one-third of India’s children aged 5 to 9 are likely living with high triglyceride levels—a key risk factor for heart disease in later life. The findings highlight significant variations across states, with regions such as West Bengal (67%), Sikkim (64%), Nagaland (55%), Assam (57%), and Jammu & Kashmir (50%) reporting the highest prevalence rates. In contrast, Kerala (16.6%) and Maharashtra (19.1%) had the lowest recorded rates.

Compiled by the Ministry of Statistics and Programme Implementation, the ‘Children in India 2025’ report draws on national surveys including the National Family Health Survey (2019-21) and the Comprehensive National Nutrition Survey (2016-18). The data show that prematurity and low birth weight account for 48% of newborn deaths in the first 29 days of life. Problems during birth, such as not getting enough oxygen, account for 16%, and pneumonia causes 9%.

Adolescent health also faces concerns, with 5% of teens classified as hypertensive. Delhi reports the highest teenage hypertension rate—10%, followed by Uttar Pradesh (8.6%), Manipur (8.3%), and Chhattisgarh (7%). Additionally, 16% of Indian adolescents are estimated to have elevated triglyceride levels.

The report also provides insights into education and child protection. Literacy among children and adolescents stands at 63.1%, while 73.1% of those aged seven and above are literate. Gender gaps remain, with boys consistently reporting higher literacy rates than girls across age brackets.

The new data underlines the urgency for both families and policymakers to prioritize early interventions targeting nutrition, preventive healthcare, and public awareness, aiming to reduce long-term risks associated with cardiovascular diseases in India’s youngest generations.

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk